Drug Trial Radar · NCT05725902
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Mar 9, 2024
Primary completion
Mar 9, 2026
Study completion Mar 9, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Feb 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.
Conditions
- Sickle Cell Disease
Interventions
EtavopivatDrug
The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of etavopivat on cerebral blood flow (CBF)Time frame: 24 weeks
- Effect of etavopivat on oxygen ejection fraction (OEF)Time frame: 24 weeks
- Effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2)Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory University Children's Healthcare of Atlanta
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.